

## ADX-1615

Aldeyra is developing an oral pro-drug of ADX-1615, for the treatment of chronic immune-mediated disorders and cancer.

# Developing Next-Generation Medicines to Improve the Lives of Patients with Immune-Mediated Diseases

### Targeting RASP

- ADX-629 for Systemic Immune-Mediated Diseases
- ADX-103 for Inflammatory Retinal Disease

### Targeting Hsp90

- ADX-1612 for Lymphoproliferative Immune Disease and Cancer
- ADX-1615 for Autoimmune Disease and Cancer

### Partnership Update

- J&J Innovation



## ADX-1615: Oral Pro-Drug of ADX-1612

- Orally administered
- Oral administration may be better suited to treatment of chronic immune-mediated disorders
- May also be useful in oncology setting
- Has shown activity in mast cell tumors in dogs (monotherapy)
  - Manuscript submitted
- Next Steps
  - Manufacturing
  - IND-enabling toxicology studies
  - Clinical testing could begin as early as 2020

Contingent on pre-clinical studies, funding, regulatory review, and other factors.

